Last edition
News about "xanthine oxidase inhibitor"
Innovent Doses First Patient in Phase III Trial of Tigulixostat for Gout
Innovent initiates Phase III study of tigulixostat against febuxostat in Chinese gout patients, aiming to deliver improved uric acid control and better safety outcomes.
Xanthine Oxidase Inhibitor | 23/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members